AIM: This the third paper in a series of three papers on the occurrence of reactions and impairments in @entity1201 in Thailand, and focuses on the prevalence and incidence of @entity73 in @entity1201 . STUDY DESIGN: A population-based, prospective cohort study. STUDY SUBJECT: All 640 newly diagnosed and registered @entity1201 @entity1 in three provinces of northeastern Thailand between October 1987 and September 1990 were included [420 paucibacillary (PB) and 220 @entity1202 ( @entity1202 )]. This group of @entity1 was followed up until the end of 1995. METHODS: Clinical data; data on the sensibility and motor function of eyes, hands and feet, and data on wounds and @entity604 were obtained where appropriate. The occurrence of @entity73 at first examination, during treatment and during surveillance was ascertained. RESULTS: The relationship between impairment prevalence (grade 2 of the combined PB and @entity1202 groups and grades 1 and 2 together of the combined PB and @entity1202 groups) and duration of disease (before diagnosis) was found to be statistically significant. Increased delay in detection led to increased problems of impairments. Too many @entity1 still develop new/additional impairments while on treatment and thereafter. The incidence of nerve function impairment (NFI) among @entity1 without impairments at first examination while on treatment was 1.7 [ 95% confidence interval (CI) 0.45-4.4] per 100 @entity1 -years at risk (PYAR) for the PB group and 12 (CI 8.4-17) per 100 PYAR for the @entity1202 group. Additionally, 2% of the PB and 11% of the @entity1202 @entity1 who already had impairments at first examination developed new NFI while on treatment. The outcome, comparing the first examination with the last examination during/after surveillance [changes in the voluntary muscle test (VMT), the @entity13317 ( @entity13317 ), wound count and @entity604 ], indicated that of the PB @entity1 3.7% improved, 3.7% got worse and 3.9% kept the same impairment; of the @entity1202 @entity1 19% improved, 18% got worse and 2.9% kept the same impairment. During treatment most of the new/additional impairments were due to new/increase in NFI; during surveillance slightly more than 50% were due to new/increase in NFI. Eighty-three percent of the @entity1202 @entity1 without impairments at first examination who developed NFI during treatment improved (completely or partially) after receiving @entity617 . Only 62% of the @entity1202 @entity1 with a grade 1 impairment at first examination and who developed a severe reaction or recent silent @entity16 improved after receiving @entity617 . There is a need for an indicator to measure new/additional impairments while on treatment and thereafter. It is proposed to measure changes in impairment by measuring changes in VMT, @entity13317 , wound count and @entity604 .

The occurrence of reactions and impairments in @entity1201 : experience in the @entity1201 control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. III. XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'person'] @entity73 :: ('MESH:D003072', 'Disease') :: ['neural and other impairments'] @entity604 :: ('MESH:D016301', 'Disease') :: ['bone loss'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy'] @entity1202 :: ('MESH:D056006', 'Disease') :: ['MB', 'multibacillary'] @entity13317 :: ('MESH:C580162', 'Disease') :: ['ST', 'sensory test'] @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone'] @entity1201 :: ('MESH:D007918', 'Disease') :: ['leprosy']
@entity73 :: (MESH:D003072,Disease) :: ['Neural and other impairments']
